Risk and risk assessment for breast cancer: molecular and clinical aspects.
Chemoprevention, prophylactic surgery and intensified screening programs are options which can be offered the patients with an increased lifetime risk (p(life)) for breast cancer (BC). Estimation of p(life) includes BRCA mutation analysis and risk estimation based on individual risk factors and family history. MENDEL and BRCAPRO are models which can estimate mutation carrier status probability (p(mut)), p(life) and p(mut) can be estimated using Cyrillic3 software which incorporates BRCAPRO and MENDEL. To integrate age, hormonal factors and benign breast biopsies in risk assessment the Tyrer-Cuzick model can be used. These models support the decision pro or contra genetic analysis and improve the number of positive gene testing results. Estimations of p(life) and p(mut), based on a mathematical model, should deal with algorithms and penetrance/frequency data adequate to the population counselled. Being the main modulatory factors, reproductive/hormonal data should be incorporated like the Tyrer-Cuzick model does.
Beckmann
M W
MW
Department of Gynaecology and Obstetrics, University Hospital Erlangen, Germany. direktion@gyn.med.uni-erlangen.de
Bani
M R
MR
Fasching
P A
PA
Strick
R
R
Lux
M P
MP
D000367:Age Factors; D001943:Breast Neoplasms / Q000235:genetics* / Q000503:physiopathology / Q000517:prevention & control; D018890:Chemoprevention; D005260:Female; D019398:Genes, BRCA1 / Q000502:physiology; D005817:Genetic Counseling; D020022:Genetic Predisposition to Disease; D012739:Gonadal Steroid Hormones; D006801:Humans; D008954:Models, Biological; D018570:Risk Assessment
D012739:Gonadal Steroid Hormones